{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T12:19:20Z","timestamp":1791893960412,"version":"4.3.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2010,2,27]],"date-time":"2010-02-27T00:00:00Z","timestamp":1267228800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Psychopharmacology"],"published-print":{"date-parts":[[2010,4]]},"DOI":"10.1007\/s00213-010-1790-2","type":"journal-article","created":{"date-parts":[[2010,2,26]],"date-time":"2010-02-26T01:56:47Z","timestamp":1267149407000},"page":"245-253","source":"Crossref","is-referenced-by-count":24,"title":["Randomized, controlled, double-blind trial of taranabant for smoking cessation"],"prefix":"10.1007","volume":"209","author":[{"given":"Mary F.","family":"Morrison","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulette","family":"Ceesay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ira","family":"Gantz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keith D.","family":"Kaufman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher R.","family":"Lines","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2010,2,27]]},"reference":[{"key":"1790_CR1","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1177\/0091270008314467","volume":"48","author":"C Addy","year":"2008","unstructured":"Addy C, Li S, Agrawal N, Stone J, Majumdar A, Zhong L et al (2008a) Safety, tolerability, pharmacokinetics, and pharmacodynamic properties of taranabant, a novel selective cannabinoid-1 receptor inverse agonist, for the treatment of obesity: results from a double-blind, placebo-controlled, single oral dose study in healthy volunteers. J Clin Pharmacol 48:418\u2013427 [Epub 2008 Feb 7]","journal-title":"J Clin Pharmacol"},{"key":"1790_CR2","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.cmet.2007.11.012","volume":"7","author":"C Addy","year":"2008","unstructured":"Addy C, Wright H, Van Laere K, Gantz I, Erondu N, Musser BJ et al (2008b) The acyclic CB1R inverse agonist taranabant mediates weight loss by increasing energy expenditure and decreasing caloric intake. Cell Metab 7:68\u201378","journal-title":"Cell Metab"},{"key":"1790_CR3","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1111\/j.1467-789X.2008.00520.x","volume":"10","author":"F Akbas","year":"2009","unstructured":"Akbas F, Gasteyger C, Sj\u00f6din A, Astrup A, Larsen TM (2009) A critical review of the cannabinoid receptor as a drug target for obesity management. Obes Rev 10:58\u201367 [Epub 2008 Aug 20]","journal-title":"Obes Rev"},{"key":"1790_CR4","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1358\/dot.2008.44.12.1308898","volume":"44","author":"AJ Alberg","year":"2008","unstructured":"Alberg AJ (2008) Cigarette smoking: health effects and control strategies. Drugs Today (Barc) 44:895\u2013904","journal-title":"Drugs Today (Barc)"},{"key":"1790_CR5","doi-asserted-by":"crossref","unstructured":"Cahill K, Ussher M (2007) Cannabinoid type 1 receptor antagonists (rimonabant) for smoking cessation. Cochrane Database Syst Rev (4):CD005353","DOI":"10.1002\/14651858.CD005353.pub3"},{"key":"1790_CR6","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1016\/S0140-6736(07)61721-8","volume":"370","author":"R Christensen","year":"2007","unstructured":"Christensen R, Kristensen PK, Bartels EM, Bliddal H, Astrup A (2007) Efficacy and safety of the weight-loss drug rimonabant: a meta-analysis of randomised trials. Lancet 370:1706\u20131713","journal-title":"Lancet"},{"key":"1790_CR7","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1503\/cmaj.070256","volume":"179","author":"MJ Eisenberg","year":"2008","unstructured":"Eisenberg MJ, Filion KB, Yavin D, B\u00e9lisle P, Mottillo S, Joseph L et al (2008) Pharmacotherapies for smoking cessation: a meta-analysis of randomized controlled trials. CMAJ 179:135\u2013144","journal-title":"CMAJ"},{"key":"1790_CR8","unstructured":"European Medicines Agency (2006) Acomplia: scientific discussion. European Medicines Agency Web site. http:\/\/ www.emea.europa.eu\/humandocs\/PDFs\/ EPAR\/acomplia\/H-666-en6.pdf. Accessed 15 Oct 2009"},{"key":"1790_CR9","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1111\/j.1467-789X.2004.00131.x","volume":"5","author":"C Filozof","year":"2004","unstructured":"Filozof C, Fern\u00e1ndez Pinilla MC, Fern\u00e1ndez-Cruz A (2004) Smoking cessation and weight gain. Obes Rev 5:95\u2013103","journal-title":"Obes Rev"},{"key":"1790_CR10","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1007\/s00213-009-1569-5","volume":"205","author":"B Forget","year":"2009","unstructured":"Forget B, Coen KM, Le Foll B (2009) Inhibition of fatty acid amide hydrolase reduces reinstatement of nicotine seeking but not break point for nicotine self-administration\u2014comparison with CB(1) receptor blockade. Psychopharmacology 205:613\u2013624","journal-title":"Psychopharmacology"},{"issue":"10 Suppl A","key":"1790_CR11","first-page":"326","volume":"51","author":"I Gantz","year":"2008","unstructured":"Gantz I, Erondu N, Suryawanshi A, Musser B, Nayee J, Johnson-Levonas AO et al (2008) A two-year study to assess the efficacy, safety, and tolerability of taranabant in obese patients: 52\u00a0week results. J Am Coll Cardiol 51(10 Suppl A):326 (Abstract 1021\u2013220)","journal-title":"J Am Coll Cardiol"},{"key":"1790_CR12","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1360-0443.2004.00540.x","volume":"99","author":"JR Hughes","year":"2004","unstructured":"Hughes JR, Keely J, Naud S (2004) Shape of the relapse curve and long-term abstinence among untreated smokers. Addiction 99:29\u201338","journal-title":"Addiction"},{"key":"1790_CR13","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1007\/3-540-26573-2_19","volume":"168","author":"AA Izzo","year":"2005","unstructured":"Izzo AA, Coutts AA (2005) Cannabinoids and the digestive tract. Handb Exp Pharmacol 168:573\u2013598","journal-title":"Handb Exp Pharmacol"},{"key":"1790_CR14","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1046\/j.1525-1497.2001.016009606.x","volume":"16","author":"K Kroenke","year":"2001","unstructured":"Kroenke K, Spitzer RL, Williams JB (2001) The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 16:606\u2013613","journal-title":"J Gen Intern Med"},{"key":"1790_CR15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14656566.9.1.15","volume":"9","author":"T Lancaster","year":"2008","unstructured":"Lancaster T, Stead L, Cahill K (2008) An update on therapeutics for tobacco dependence. Expert Opin Pharmacother 9:15\u201322","journal-title":"Expert Opin Pharmacother"},{"key":"1790_CR16","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1124\/jpet.104.077974","volume":"312","author":"B Foll Le","year":"2005","unstructured":"Le Foll B, Goldberg SR (2005) Cannabinoid CB1 receptor antagonists as promising new medications for drug dependence. J Pharmacol Exp Ther 312:875\u2013883 [Epub 2004 Nov 3]","journal-title":"J Pharmacol Exp Ther"},{"key":"1790_CR17","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/j.1369-1600.2008.00113.x","volume":"13","author":"B Foll Le","year":"2008","unstructured":"Le Foll B, Forget B, Aubin HJ, Goldberg SR (2008) Blocking cannabinoid CB1 receptors for the treatment of nicotine dependence: insights from pre-clinical and clinical studies. Addict Biol 13:239\u2013252","journal-title":"Addict Biol"},{"key":"1790_CR18","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s00213-009-1506-7","volume":"205","author":"B Foll Le","year":"2009","unstructured":"Le Foll B, Gorelick DA, Goldberg SR (2009) The future of endocannabinoid-oriented clinical research after CB(1) antagonists. Psychopharmacology (Berl) 205:171\u2013174 [Epub 2009 Mar 20]","journal-title":"Psychopharmacology (Berl)"},{"key":"1790_CR19","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S1734-1140(09)70025-8","volume":"61","author":"CE Leite","year":"2009","unstructured":"Leite CE, Mocelin CA, Petersen GO, Leal MB, Thiesen FV (2009) Rimonabant: an antagonist drug of the endocannabinoid system for the treatment of obesity. Pharmacol Rep 61:217\u2013224","journal-title":"Pharmacol Rep"},{"key":"1790_CR20","doi-asserted-by":"crossref","first-page":"7584","DOI":"10.1021\/jm060996+","volume":"49","author":"LS Lin","year":"2006","unstructured":"Lin LS, Lanza TJ Jr, Jewell JP, Liu P, Shah SK, Qi H et al (2006) Discovery of N-[(1\u00a0S, 2\u00a0S)-3-(4-Chlorophenyl)-2- (3-cyanophenyl)-1-methylpropyl]-2-methyl-2- {[5-(trifluoromethyl)pyridin-2-yl]oxy}propanamide (MK-0364), a novel, acyclic cannabinoid-1 receptor inverse agonist for the treatment of obesity. J Med Chem 49:7584\u20137587","journal-title":"J Med Chem"},{"issue":"4 Suppl 1","key":"1790_CR21","doi-asserted-by":"crossref","first-page":"S20","DOI":"10.1016\/j.amjmed.2008.01.016","volume":"121","author":"M Nides","year":"2008","unstructured":"Nides M (2008) Update on pharmacologic options for smoking cessation treatment. Am J Med 121(4 Suppl 1):S20\u2013S31","journal-title":"Am J Med"},{"key":"1790_CR22","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1136\/bmj.39385.413113.25","volume":"335","author":"D Rucker","year":"2007","unstructured":"Rucker D, Padwal R, Li SK, Curioni C, Lau DC (2007) Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ 335:1194\u20131199","journal-title":"BMJ"},{"issue":"8","key":"1790_CR23","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1046\/j.1360-0443.2000.95811855.x","volume":"95","author":"S Shiffman","year":"2000","unstructured":"Shiffman S, Elash CA, Paton SM, Gwaltney CJ, Paty JA, Clark DB, Liu KS, Di Marino ME (2000) Comparative efficacy of 24-hour and 16-hour transdermal nicotine patches for relief of morning craving. Addiction 95(8):1185\u20131195","journal-title":"Addiction"},{"key":"1790_CR24","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00213-002-1338-1","volume":"166","author":"S Shiffman","year":"2003","unstructured":"Shiffman S, Shadel WG, Niaura R, Khayrallah MA, Jorenby DE, Ryan CF, Ferguson CL (2003) Efficacy of acute administration of nicotine gum in relief of cue-provoked cigarette craving. Psychoparmacology 166:343\u2013350","journal-title":"Psychoparmacology"},{"key":"1790_CR25","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1001\/jama.282.18.1737","volume":"282","author":"RL Spitzer","year":"1999","unstructured":"Spitzer RL, Kroenke K, Williams JB (1999) Validation and utility of a self-report version of PRIME-MD: the PHQ primary care study. Primary care evaluation of mental disorders. Patient health questionnaire. JAMA 282:1737\u20131744","journal-title":"JAMA"},{"key":"1790_CR26","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.jdermsci.2005.01.007","volume":"38","author":"S St\u00e4nder","year":"2005","unstructured":"St\u00e4nder S, Schmelz M, Metze D, Luger T, Rukwied R (2005) Distribution of cannabinoid receptor 1 (CB1) and 2 (CB2) on sensory nerve fibers and adnexal structures in human skin. J Dermatol Sci 38:177\u2013188","journal-title":"J Dermatol Sci"},{"key":"1790_CR27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s00213-003-1485-z","volume":"169","author":"G Tanda","year":"2003","unstructured":"Tanda G, Goldberg SR (2003) Cannabinoids: reward, dependence, and underlying neurochemical mechanisms\u2014a review of recent preclinical data. Psychopharmacology (Berl) 169:115\u2013134 [Epub 2003 Jun 24]","journal-title":"Psychopharmacology (Berl)"}],"container-title":["Psychopharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-1790-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00213-010-1790-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00213-010-1790-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,23]],"date-time":"2019-05-23T16:07:10Z","timestamp":1558627630000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00213-010-1790-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2,27]]},"references-count":27,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2010,4]]}},"alternative-id":["1790"],"URL":"https:\/\/doi.org\/10.1007\/s00213-010-1790-2","relation":{},"ISSN":["0033-3158","1432-2072"],"issn-type":[{"value":"0033-3158","type":"print"},{"value":"1432-2072","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,2,27]]}}}